ArticleJournal of thoracic disease2018
Serum microRNAs improving the diagnostic accuracy in lung cancer presenting with pulmonary nodules.
Article in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Biomarkers Suitable for Early Detection of Intrathoracic Cancers in Primary Care: A Systematic Review.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Pooled it
- Meta analysis of the diagnostic value of circulating miRNA in benign and malignant pulmonary nodules.World journal of surgical oncology · 2023Pooled it
- Pulmonary nodules: classification, biomarkers, signaling pathways, diseases, early diagnosis and management.Signal transduction and targeted therapy · 2026Review
- Application of liquid biopsy in differentiating lung cancer from benign pulmonary nodules (Review).International journal of molecular medicine · 2025Review
- Clinical value of peripheral blood miR-21 and miR-486 combined with CT forearly cancer diagnosis in pulmonary nodulessmoking.Journal of cardiothoracic surgery · 2024Article
- Clinical Scores, Biomarkers and IT Tools in Lung Cancer Screening-Can an Integrated Approach Overcome Current Challenges?Cancers · 2023Review
- miR-199a: A Tumor Suppressor with Noncoding RNA Network and Therapeutic Candidate in Lung Cancer.International journal of molecular sciences · 2022Review
- Salivary microRNA profiling dysregulation in autism spectrum disorder: A pilot study.Frontiers in neuroscience · 2022Article
- miR-199a-3p plays an anti-tumorigenic role in lung adenocarcinoma by suppressing anterior gradient 2.Bioengineered · 2021Article
- Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.International journal of molecular sciences · 2021Review
- The promises and challenges of early non-small cell lung cancer detection: patient perceptions, low-dose CT screening, bronchoscopy and biomarkers.Molecular oncology · 2021Review
- The diagnostic value of miR-21 combined with CT in patients with liver cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Liquid biopsies to distinguish malignant from benign pulmonary nodules.Thoracic cancer · 2021Review
- Down-Regulation of ZEB1 by miR-199a-3p Overexpression Restrains Tumor Stem-Like Properties and Mitochondrial Function of Non-Small Cell Lung Cancer.OncoTargets and therapy · 2020Article
- Article
- Use of amantadine as substrate for SSAT-1 activity as a reliable clinical diagnostic assay for breast and lung cancer.Future science OA · 2019Article
- Exploration and validation of downregulated microRNA-199a-3p, downstream messenger RNA targets and transcriptional regulation in osteosarcoma.American journal of translational research · 2019Article
- Downregulation of miR-199a-3p in Hepatocellular Carcinoma and Its Relevant Molecular Mechanism via GEO, TCGA Database and In Silico Analyses.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNA (miRNA) is an approach for early diagnosing of cancer. We validated a panel of miRNAs (hsa-miR-199a-3p, hsa-miR-148a-3p, hsa-miR-210-3p, hsa-miR-378d and hsa-miR-138-5p) to aid early diagnosis of lung adenocarcinoma by blood test in lung cancer presenting with pulmonary nodules.
methodsA total of 369 individuals who were detected pulmonary nodules by computed tomography (CT) scan were enrolled into this study. These patients included 274 pulmonary malignant or borderline lung diseases and 122 lung benign pulmonary nodules. When the lung nodules were detected by combining with CT scan, we got patient blood samples in 2 days. Patients' serum was collected within 2 days prior to miRNAs analyses. We performed miRNAs panel by reverse transcription-polymerase chain reaction (RT-PCR).
resultsThe sensitivity of miRNAs panel was 34.0% and the specificity of miRNAs panel was 90.2%. In invasive adenocarcinoma, the sensitivity of miRNAs panel was 44.7%. The overall false positive rate of CT imaging for nodules and glass ground nodules (GGNs) was 33.1%. When miRNAs panel test positive patients combined with the nodule size, the false positive rate was decreased to 3.2%.
conclusionsThe greatest impact of using the miRNAs panel CT scan was decreasing the false positive. miRNAs panel can improve the diagnosis of lung cancer presenting with nodules combined with CT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.